Monoclonal antibody specifically bound with trypsin protein and application of monoclonal antibody in detection
By using a highly specific anti-recombinant trypsin protein monoclonal antibody in the kit and using the double-anti-sandwich method, the problems of low sensitivity and poor specificity of the existing detection methods are solved, and the high accuracy of recombinant trypsin protein is achieved. Quantitative detection is characterized by rapid, simple, high specificity and high sensitivity.
Patent Information
- Application Number
- CN202310637214.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The existing quantitative detection methods of recombinant trypsin proteins have low sensitivity, poor specificity, complex operation, and difficult to achieve high-accurate trace detection.
A kit containing highly specific anti-recombinant trypsin protein monoclonal antibodies was developed. The dual-anti-sandwich method uses the binding of two different epitopes to improve the sensitivity and specificity of the detection, including CCTCC NO :C202321 and CCTCC NO:C202320 Monoclonal antibodies secreted by hybridoma cell lines.
Accurate quantitative detection of recombinant trypsin proteins is achieved, with sensitivity reaching 0.049ng/mL and linear range of 0.02-40ng/ml. The detection is fast, accurate, simple, and has high specificity, avoiding non-specific binding and improving the detection results. accuracy and precision.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of immunoassay, and in particular relates to a hybridoma cell capable of secreting anti-trypsin protein monoclonal antibody, a monoclonal antibody and applications thereof, wherein the trypsin comprises recombinant trypsin. Background Art
[0002] Recombinant porcine trypsin (RPT) protein specifically cleaves lysine and arginine C-terminal peptide bonds, enabling the degradation of intercellular binding proteins. The amino acid sequence of recombinant trypsin protein is identical to porcine pancreatic trypsin and is expressed in recombinant Escherichia coli. It can replace traditional extracted trypsin in cell digestion processes for vaccines, stem cell therapy, immune cell therapy, drug screening, and antibody applications.
[0003] In modern biopharmaceutical production, the greatest potential risk associated with the use of animal-derived raw materials is the potential introduction of potential zoonotic viruses. Recombinant trypsin production does not use any animal-derived raw materials. It is safe to use due to the absence of exogenous viral contamination. It is widely used in: (1) biological reagents for recombinant protein drugs, such as insulin and analogue biological reagents, GLP-1 analogue biological reagents; (2) various cell cultures, such as vaccine biological reagents, stem cell isolation, etc.; (3) protein structure and function research, such as protein mass spectrometry, sequencing, and peptide mapping analysis; and (4) biological reagents for small molecule proteins or peptides, such as cosmetic peptides, antimicrobial peptides, and food flavor peptide biological reagents. Therefore, quantitative detection or control of recombinant trypsin protein is particularly important.
[0004] Although enzyme-linked immunosorbent assays (ELISAs) have been developed for the quantitative determination of recombinant trypsin protein, currently available commercial kits suffer from low sensitivity, poor specificity, and complex operation. Therefore, further improvements and the development of reagents with accurate and highly sensitive results are crucial for the quantitative (trace) detection of recombinant trypsin protein. The core raw materials required for these assays are specific antigens or antibodies.
[0005] Based on the above, preparing highly specific and sensitive RPT antibodies has become a technical problem that needs to be solved urgently by those skilled in the art. Summary of the Invention
[0006] The purpose of the present invention is to provide a hybridoma cell capable of secreting anti-recombinant trypsin protein (RPT) monoclonal antibody, a monoclonal antibody and an application thereof.
[0007] In a first aspect of the present invention, a kit for detecting trypsin protein is provided, comprising: (i) a monoclonal antibody secreted by a hybridoma cell line (TE-5C2D12) with a deposit number of CCTCC NO: C202321; and (ii) a monoclonal antibody secreted by a hybridoma cell line (TE-1E10A5) with a deposit number of CCTCC NO: C202320.
[0008] In one or more preferred embodiments, the kit comprises:
[0009] A solid phase carrier coated with a first monoclonal antibody, wherein the first monoclonal antibody is selected from the monoclonal antibody of (i) or (ii); and
[0010] A container or package a, wherein the container or package a contains a second monoclonal antibody, wherein the second monoclonal antibody is selected from the monoclonal antibody of (ii) or (i);
[0011] Wherein, the second monoclonal antibody carries a detectable label; or, the kit comprises a detectable label for linking with the second monoclonal antibody;
[0012] The first monoclonal antibody and the second monoclonal antibody are different and can bind to trypsin protein at the same time.
[0013] In one or more preferred embodiments, the first monoclonal antibody is preferably antibody (i), and the second monoclonal antibody is preferably antibody (ii).
[0014] In one or more preferred embodiments, the kit further comprises one or more components selected from the following:
[0015] (a) container or package b, wherein the container or package b contains a trypsin protein standard (positive standard); and / or
[0016] (b) a container or package c containing a quality control product of trypsin protein; preferably, the quality control product includes a positive quality control product and a negative quality control product;
[0017] (c) a container or package d containing a substrate corresponding to a detectable label;
[0018] (d) a container or package e containing a developer;
[0019] (e) a container or package f, wherein the container or package f contains a coating liquid;
[0020] (f) a container or package g containing a washing liquid;
[0021] (g) a container or package f containing a stop solution.
[0022] In one or more preferred embodiments, the detectable label includes (but is not limited to): horseradish peroxidase, alkaline phosphatase, glucose oxidase, β-D-galactosidase, urease, catalase, or glucoamylase.
[0023] In one or more preferred embodiments, the solid phase carrier includes (but is not limited to): well plates (including microtiter plates), magnetic beads, microspheres, chips, glass slides, and test paper.
[0024] In one or more preferred embodiments, the linear range value of the kit is 0.02-40 ng / ml.
[0025] In one or more preferred embodiments, the detection sensitivity of the kit is 0.049 ng / mL.
[0026] In one or more preferred embodiments, the kit is an enzyme-linked immunosorbent assay (ELISA) detection kit.
[0027] In one or more preferred embodiments, the trypsin protein comprises recombinant trypsin protein.
[0028] In one or more preferred embodiments, the trypsin protein comprises a trypsin protein having an amino acid sequence as shown in SEQ ID NO: 1.
[0029] In another aspect of the present invention, a monoclonal antibody that specifically binds to trypsin protein is provided, selected from: (i) a monoclonal antibody secreted by the hybridoma cell line (TE-5C2D12) with a deposit number of CCTCC NO: C202321; (ii) a monoclonal antibody secreted by the hybridoma cell line (TE-1E10A5) with a deposit number of CCTCC NO: C202320.
[0030] In one or more preferred embodiments, the monoclonal antibody is used to prepare a kit for detecting trypsin protein.
[0031] In one or more preferred embodiments, the detection includes quantitative detection, semi-quantitative detection or qualitative detection.
[0032] In another aspect of the present invention, a hybridoma cell line that produces a monoclonal antibody that specifically binds to trypsin protein is provided, selected from: a hybridoma cell line (TE-5C2D12) with a preservation number of CCTCC NO: C202321; a hybridoma cell line (TE-1E10A5) with a preservation number of CCTCC NO: C202320.
[0033] In another aspect of the present invention, a method for detecting trypsin protein is provided, the method comprising the following steps:
[0034] (a) adding a sample to be tested to a solid phase carrier coated with a first monoclonal antibody, so that trypsin in the sample to be tested binds to the first monoclonal antibody on the solid phase carrier to form a solid phase carrier with a "trypsin protein-first monoclonal antibody" binary complex;
[0035] (b) adding a second monoclonal antibody to the solid phase support obtained in (a), thereby forming a solid phase support with a "second monoclonal antibody-trypsin protein-first monoclonal antibody" ternary complex; wherein the second monoclonal antibody carries a label;
[0036] (c) detecting the marker in the ternary complex, thereby determining whether and how much trypsin protein is present in the sample to be tested;
[0037] The additional proviso is that step (a) and step (b) may be performed sequentially or simultaneously;
[0038] The first monoclonal antibody and the second monoclonal antibody are selected from: a monoclonal antibody secreted by a hybridoma cell line with a deposit number of CCTCC NO: C202321, and a monoclonal antibody secreted by a hybridoma cell line with a deposit number of CCTCC NO: C202320; preferably, the first monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell line with a deposit number of CCTCC NO: C202321, and the second monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell line with a deposit number of CCTCC NO: C202320.
[0039] In one or more preferred embodiments, the method for detecting trypsin protein is an in vitro method.
[0040] In one or more preferred embodiments, the method for detecting trypsin protein is a non-diagnostic method.
[0041] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1These are the specificity test results of the monoclonal antibodies TE-1E10A5 and TE-5C2D12 in Example 2.
[0043] Figure 2 This is the result of the upper limit of the test kit used in the application.
[0044] Figure 3 This is the result of the lower detection limit of the kit used in the application. DETAILED DESCRIPTION
[0045] After extensive research, the inventors have isolated hybridoma cells that secrete anti-trypsin monoclonal antibodies. These antibodies are highly specific, possess excellent antigen-binding properties, and target different epitopes of trypsin. Based on the principle of a double-antibody sandwich assay, a simple, highly accurate, and rapid test kit for the presence of trypsin has been developed, enabling precise quantitative detection of recombinant trypsin protein.
[0046] Those skilled in the art will appreciate that an antigen may contain multiple epitopes (antigenic determinants). Therefore, more than one antibody may be obtained for the same antigen, and the binding properties (such as specificity, etc.) of these antibodies to the antigen may all be different. Therefore, for the same antigen, those skilled in the art need to compare and screen to find a monoclonal antibody suitable for specific binding. Due to the spatial structure of the antigen, many epitopes are contained within the interior of the spatial structure, making it difficult to find an antibody that can specifically bind to an epitope that is stably present outside the spatial structure. The inventor has conducted in-depth research and has isolated and obtained a monoclonal antibody that is highly specific to trypsin protein and is particularly suitable for a double-antibody sandwich method.
[0047] In the present invention, the target object of detection is trypsin protein. In a preferred embodiment, the target object of detection of the present invention is recombinant trypsin. Natural source (animal source) trypsin has the risk of contamination, etc., while recombinant trypsin belongs to the source of prokaryotic or eukaryotic expression system, and the risk of contamination is small. Therefore, recombinant trypsin is preferably used, and the antibody of the present invention can achieve accurate detection of recombinant trypsin. A single anti-trypsin protein antibody is easily interfered with when used for detection, resulting in poor specificity and large deviation in results. Under normal circumstances, if an antibody is used to bind to trypsin protein, non-specific binding may inevitably occur during the determination process; and based on the principle of double antibody sandwich method to prepare the kit, using double antibodies that bind to different epitopes of trypsin protein antigen, the probability of non-specific binding in this case is very low, so the accuracy and precision of the results are high.
[0048] Furthermore, the two highly specific antibodies of the present invention are used to adsorb and locate the target antigen trypsin protein, which has better localization and amplification effects, thereby achieving higher specificity and precision. Furthermore, only a small amount of sample is required for the assay.
[0049] As used herein, the "capture antibody", "coating antibody", "first monoclonal antibody", "first antibody", and "primary antibody" are used interchangeably and refer to an antibody specific for anti-trypsin protein that is immobilized on a solid support.
[0050] As used herein, the terms "detection antibody," "second monoclonal antibody," "secondary antibody," "enzyme-labeled antibody," and "secondary antibody" are used interchangeably to refer to an antibody that specifically targets trypsin and corresponds to the corresponding primary antibody in the kit. For the antigen trypsin, the corresponding primary and secondary antibodies are different and can simultaneously bind to different epitopes (antigenic determinants) of the trypsin.
[0051] As used herein, "test sample" encompasses a variety of sample types, including various objects requiring trypsin content testing. For example, the "test sample" may be (1) biological reagents for recombinant protein drugs, such as insulin and analog biological reagents, GLP-1 analog biological reagents; (2) various cell cultures, such as vaccine biological reagents, stem cell isolation, etc.; (3) protein structure and function research, such as protein mass spectrometry, sequencing, and peptide mapping analysis; (4) biological reagents for small molecule proteins or peptides, such as biological reagents for beauty peptides, antimicrobial peptides, and food flavor peptides, etc.
[0052] As used herein, the "label" or "detectable marker" refers to a label located on or attachable to the second monoclonal antibody for use in determining the presence and amount of trypsin protein in a sample to be tested. Preferably, the label can be selected from horseradish peroxidase (HRP), alkaline phosphatase (AP), glucose oxidase, β-D-galactosidase, urease, catalase, or glucoamylase.
[0053] As used herein, the term "substrate corresponding to a detectable marker" refers to a substance that can be catalyzed by the marker of the second monoclonal antibody to develop a color that indicates binding of the second antibody to the trypsin protein. Examples of such substrates include o-phenylenediamine (OPD), tetramethylbenzidine (TMB), and ABTS for horseradish peroxidase; and p-nitrophenyl phosphate (p-NPP) for alkaline phosphatase.
[0054] As used herein, the "double antibody sandwich method" is a type of enzyme-linked immunosorbent assay (ELISA). The conventional approach is to immobilize a primary antibody on a carrier, react the primary antibody with the antigen, wash it, then react with a labeled secondary antibody, wash it, and finally detect the signal using chemiluminescence or enzyme-linked colorimetric development. The double antibody sandwich method is suitable for detecting antigens with two or more epitopes, but the prerequisite is that two antibodies targeting different epitopes with excellent binding properties are required. In this field, polyclonal antibodies are commonly used as secondary antibodies, but their specificity or sensitivity is often lacking.
[0055] Trypsin
[0056] Trypsin is a known protein, and its amino acid sequence and nucleotide sequence are both known in the art. The amino acid sequence of the recombinant trypsin described in the present invention is shown in SEQ ID NO: 1.
[0057] Methods for producing trypsin proteins are also known. For example, by conventional recombinant DNA technology, the polynucleotide sequence of trypsin proteins can be utilized to express or produce recombinant trypsin proteins. Generally speaking, the following steps are involved:
[0058] (1) Transforming or transducing a suitable host cell with a polynucleotide encoding a trypsin protein (or variant), or a recombinant expression vector containing the polynucleotide;
[0059] (2) Host cells cultured in a suitable culture medium; and
[0060] (3) Isolate and purify proteins from culture medium or cells.
[0061] The recombinant trypsin protein obtained above can be processed into a protein with a certain purity and used to prepare a standard product.
[0062] Monoclonal antibody against trypsin
[0063] The antibodies used in the present invention are monoclonal antibodies that are specific for trypsin. Here, "specificity" refers to the ability of the antibody to bind to trypsin or its fragments. More particularly, it refers to antibodies that can bind to trypsin or its fragments but do not recognize and bind to other non-related antigenic molecules.
[0064] The present invention utilizes highly specific monoclonal antibodies targeting different epitopes of trypsin protein and prepares a kit for convenient, rapid and accurate analysis of trypsin protein based on the principle of double antibody sandwich method.
[0065] The codes and accession numbers of the two antibodies are as follows:
[0066] Hybridoma cell line TE-1E10A5, deposited as CCTCC NO: C202320, IgG1 subtype;
[0067] The hybridoma cell line TE-5C2D12 has a deposit number of CCTCC NO: C202321 and an IgG1 subtype.
[0068] The monoclonal antibodies of the present invention can be prepared using hybridoma technology (see Kohler et al., Nature 256;495, 1975; Kohler et al., Eur. J. Immunol. 6:511, 1976; Kohler et al., Eur. J. Immunol. 6:292, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, NY, 1981). The monoclonal antibodies of the present invention can be obtained using trypsin proteins, fragments, or functional regions by conventional immunoassay techniques. In addition, they can also be prepared using recombinant methods or synthesized using a peptide synthesizer.
[0069] In one embodiment of the present invention, the monoclonal antibody can be prepared by the following preparation method, which includes the steps of: (1) providing mice pretreated with an adjuvant; (2) inoculating the hybridoma cells secreting the monoclonal antibody into the mouse peritoneal cavity; (3) extracting ascites and isolating the monoclonal antibody. As a preferred method, the method for isolating the monoclonal antibody from ascites can be a method of collecting ascites, affinity purification, and dialysis. For example, it can include: collecting ascites, precipitating with ammonium sulfate and octanoic acid, and then purifying with a Protein G pre-packed chromatography column to obtain a high-purity monoclonal antibody.
[0070] In addition, the hybridoma cells can also be cultured and expanded in vitro according to conventional animal cell culture methods, so as to secrete the monoclonal antibody.
[0071] After obtaining the antibody of the present invention, those skilled in the art can obtain the sequence information of the monoclonal antibody by sequencing techniques known in the art, such as determining the sequences of its heavy and light chains, and thus can apply bioengineering techniques to artificially prepare the antibody.
[0072] The monoclonal antibodies of the present invention can be prepared by recombinant methods or synthesized using a peptide synthesizer. Those skilled in the art will appreciate that after obtaining a hybridoma cell line producing the monoclonal antibody or identifying the monoclonal antibody through sequencing or other means, those skilled in the art can readily obtain the antibody.
[0073] The monoclonal antibodies of the present invention are derived from specific hybridoma cell lines. It should be understood that after obtaining the antibodies of the present invention from the cell lines, various modifications can be made to the antibodies, or they can be sequenced, and optimized and modified based on the sequenced antibody structure. These antibody variations are all within the scope of the present invention. Therefore, the antibodies of the present invention can be complete immunoglobulin molecules or antigen-binding fragments, including but not limited to Fab, F(ab'), F(ab')2, Fv, dAb, Fd, complementary determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain antibodies, bispecific diabodies, three-chain antibodies, and four-chain antibodies.
[0074] The present invention also provides an immunoconjugate comprising the antibody described herein and further comprising at least one other type of functional molecule. The functional molecule includes, but is not limited to, a detectable label. The antibody and the functional molecule can be covalently linked, coupled, attached, cross-linked, or the like to form the conjugate.
[0075] After determining the coating antibody and / or detection antibody used in the kit of the present invention, various detectable labels conventionally used in the art for binding to the detection antibody for detection can be used. The present invention has no particular limitation on the label used, as long as it can bind to the monoclonal antibody of the present invention and accurately indicate the presence or absence and amount of the target protein in the sample to be detected after appropriate treatment. The detectable label may include, but is not limited to: colloidal gold, fluorescent labels, colorimetric labels; such as: enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron-emitting metals, and non-radioactive paramagnetic metal ions. It may also contain more than one label. The label used to label the antibody for detection and / or analysis purposes depends on the specific detection / analysis technology and / or method used, such as immunohistochemical staining (tissue) samples, flow cytometry, etc. Suitable labels for detection / analysis technologies and / or methods known in the art are well known to those skilled in the art.
[0076] The marker can be directly set on the detection antibody; alternatively, the marker can also be set on the anti-antibody of the specific anti-second antibody. Those skilled in the art can select a suitable marker according to the type and characteristics of the antibody used. For example, the marker can be selected from: horseradish peroxidase (HRP), alkaline phosphatase (AP), glucose oxidase, β-D-galactosidase, urease, catalase, glucoamylase or biotin. When using some enzyme markers as shown above, it is also necessary to use some substrates that bind to the corresponding enzymes, so that the presence or amount of the marker can be reported by color development or other means. As used herein, the "substrate corresponding to the marker" refers to a substrate that can be catalyzed by the marker to develop color, which is used to display the recognition signal of the binding of the second antibody to the target protein. Examples of substrates include o-phenylenediamine (OPD), tetramethylbenzidine (MB), and ABTS for horseradish peroxidase; p-nitrophenyl phosphate (p-NPP) for alkaline phosphatase; and phycoerythrin (streptavidin-phycoerythrin, also known as PE-labeled streptavidin, SA-R-PE) for biotin. Those skilled in the art can select an appropriate substrate based on the type and properties of the label used.
[0077] As a specific example, the detectable marker is HRP, which serves as a display marker and generates a signal when combined with OPD, MB or ABTS.
[0078] Reagent test kit
[0079] After obtaining the monoclonal antibodies of the present invention, those skilled in the art can sensitively detect the presence or concentration of trypsin in a sample through a variety of methods, using techniques commonly used in the field of immunology. These include qualitative and quantitative detection methods. Preferably, the qualitative detection includes: identifying the presence of trypsin by immunoblotting or immunofluorescence; for example, measuring trypsin by ELISA, immunocolloidal gold test strips, immunofluorescence test strips, homogeneous enzyme immunoassay, and the like. The present invention provides a kit for detecting trypsin, which can be used to detect trypsin, etc.
[0080] The kit contains the monoclonal antibodies of the present invention. In a preferred embodiment, one of the monoclonal antibodies is immobilized on a solid phase carrier, and the other serves as a detection antibody.
[0081] In a preferred embodiment of the present invention, the first monoclonal antibody is a monoclonal antibody secreted by the hybridoma cell line (TE-5C2D12) with a deposit number of CCTCC NO: C202321; and the second monoclonal antibody is a monoclonal antibody secreted by the hybridoma cell line (TE-1E10A5) with a deposit number of CCTCC NO: C202320. Surprisingly, the combination of TE-5C2D12 as the coating antibody and TE-1E10A5 as the detection antibody yielded the best trypsin protein detection, with a sensitivity of approximately 0.049 ng / mL.
[0082] The first monoclonal antibody is coated on a solid phase carrier. The present invention has no particular limitation on the solid phase carrier used, as long as it can be coupled (connected) to the first monoclonal antibody. For example, the solid phase carrier is selected from: a microtiter plate, or a microsphere, etc.
[0083] As an operation example, the solid phase carrier used can be a microtiter plate (enzyme labeling plate).
[0084] In order to eliminate false positives and false negatives, it is advisable to set a quality control (control) during the detection process. In one embodiment of the present invention, the quality control product adopts a trypsin protein standard.
[0085] In addition, to obtain quantitative results, multiple trypsin protein standards containing known concentrations can be set during the assay. Conventional methods can be used to set up these standards.
[0086] Using the standard, a standard curve is set up as follows: the OD value of the standard is plotted as the ordinate (Y-axis) and the concentration of the standard is plotted as the abscissa (X-axis) to form a quantitative standard curve for the trypsin protein assay kit. Thus, based on the OD value obtained from the test sample, the concentration of trypsin protein in the test sample can be calculated using the standard curve.
[0087] Furthermore, to facilitate detection, the kit of the present invention preferably also includes other auxiliary reagents. These auxiliary reagents are commonly used in double antibody sandwich assays, and the properties and preparation methods of these reagents are well known to those skilled in the art. Examples of such reagents include (but are not limited to): a color developer, a wash solution, a stop solution, and a sensitization diluent.
[0088] The beneficial effects of the present invention are mainly:
[0089] (1) Because the kit of the present invention uses monoclonal antibodies that have high affinity for trypsin and highly specific recognition of different epitopes of trypsin, the sensitivity and accuracy are very high. Its linear range is 0.02-40 ng / ml. The ELISA kit can be used for quantitative (trace) detection of recombinant trypsin protein.
[0090] (2) Since the monoclonal antibody used has extremely excellent binding properties for trypsin protein, the kit of the present invention can detect trypsin protein in the blood extremely quickly, in a short time, and is faster than ordinary ELISA kits of the same type.
[0091] (3) The kit of the present invention is also simple and stable.
[0092] The present invention will be further described below with reference to specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. Experimental procedures in the following examples, where specific conditions are not specified, were generally performed under conventional conditions, such as those described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.
[0093] Example 1. Obtaining a hybridoma cell line capable of secreting monoclonal antibodies against recombinant trypsin protein The amino acid sequence of the recombinant trypsin protein (RPT) used as an immunogen is shown below (SEQ ID NO: 1):
[0094] FPTDDDDKIVGGYTCAANSIPYQVSLNSGSHFCGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDVLEGNEQFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLNSRVATVSLPR SCAAAGTECLISGWGNTKSSGSSYPSLLQCLKAPVLSDSSCKSSYPGQITGNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCAQKNKPGVYTKVCNYVNWIQQTIAAN
[0095] Based on the full-length RPT sequence, restriction sites EcoRI and SalI, along with protective bases, were added to both ends of the coding sequence for full gene synthesis. The double-enzyme digested vector PET28A(+) was then ligated with the RPT gene fragment, resulting in recombinant plasmid construction and sequencing. The RPT recombinant plasmid, identified as correct by sequencing, was transformed into BL21 cells, harvested, lysed, and purified. The purified recombinant trypsin protein (RPT) was diluted with saline to a concentration of 500 μg / mL and mixed with an equal volume of Sigma-Freund's complete adjuvant. 100 μL of the purified recombinant trypsin protein (RPT) was injected intramuscularly into the back of two 6-week-old Balb / c mice. Subsequently, two booster doses of the recombinant trypsin protein (RPT) were administered 14 days apart, diluted with saline to a concentration of 500 μg / mL and mixed with an equal volume of Sigma-Freund's incomplete adjuvant. Following the third dose, blood was collected from the mice's tails, and serum titers were determined by indirect ELISA. The titers met the fusion requirement. Three days before cell fusion, spleens were boosted with 100 μg of protein.
[0096] Balb / c mouse spleen cells were mixed with SP2 / 0 myeloma cells in the logarithmic growth phase at a ratio of 9:1 and fused under the action of 50% PEG1500. After fusion, the cells were cultured in 1640-HAT complete medium containing 10% FBS (fetal bovine serum) for 6-7 days. Cell clones were selected and cultured in 1640-HT complete medium for screening. After 5 days of culture, the antibody specificity in the cell culture supernatant was detected by indirect ELISA. A monoclonal cell line that can stably secrete antibodies was obtained. After expansion culture, it was frozen in FBS containing 10% DMSO at a cell density of 10 6 Ascites was prepared by in vivo induction method, and purified by Protein G affinity chromatography to obtain purified antibodies. After dialysis against 0.01 mol / L phosphate buffer, the protein concentration was measured at OD280nm, and multiple monoclonal antibodies were selected.
[0097] Conduct an antibody pairing experiment: Multiple antibodies secreted by multiple monoclonal cell lines are coated onto microtiter plates and labeled with biotin, where they are then fully matched to form paired antibodies. The screening method is a double-antibody sandwich ELISA. The screening principle is as follows: After obtaining monoclonal antibodies, two monoclonal antibodies are removed, one serving as a capture antibody and the other as a labeled antibody. The capture antibody is coated onto an antigen plate. Antigen is added, incubated, and unbound antigen is washed away. The labeled antibody is then added, incubated, and unbound labeled antibody is washed away. Finally, a colorimetric solution is added to develop color. If color develops, it indicates that the labeled antibody specifically binds to the antigen, and the capture and labeled antibodies are a paired pair. If no color develops, it indicates that the labeled antibody cannot bind to the antigen and is washed away, and the capture and labeled antibodies are not a paired pair.
[0098] The two best cell lines that can stably secrete monoclonal antibodies and can be paired for double antibody sandwich testing were screened from the monoclonal cell lines. They were named hybridoma cells TE-1E10A5 and TE-5C2D12 that can secrete anti-recombinant trypsin protein (RPT) monoclonal antibodies.
[0099] Table 1. Pairing of different monoclonal antibodies*
[0100]
[0101] *Note: - means unable to match; + means able to match, but the positive result is weak; ++ means able to match, but the positive result is strong; +++ means able to match, but the positive result is the strongest.
[0102] Hybridoma cells TE-1E10A5 and TE-5C2D12 were deposited with the China Center for Type Culture Collection under accession numbers CCTCC NO: C202320 and CCTCC NO: C202321, respectively. Hybridoma cells TE-1E10A5 and TE-5C2D12 secrete monoclonal antibodies against recombinant trypsin protein (RPT). The monoclonal antibodies secreted by the hybridoma cell lines TE-1E10A5 and TE-5C2D12 were designated monoclonal antibodies TE-1E10A5 and TE-5C2D12, respectively.
[0103] Example 2. Preparation, Purification and Titering of Monoclonal Antibodies TE-1E10A5 and TE-5C2D12
[0104] 1. Preparation of Monoclonal Antibodies TE-1E10A5 and TE-5C2D12
[0105] 1. Incremental cultivation method
[0106] Preparation method of cell culture medium: fetal bovine serum was added to RPMI-1640 culture medium, and the final concentration of fetal bovine serum was 10% (mass percentage).
[0107] Hybridoma cell lines TE-1E10A5 and TE-5C2D12 were placed in cell culture medium and cultured at 37°C for 3-4 days. The cell culture supernatant was purified by Protein A affinity chromatography to obtain monoclonal antibodies TE-1E10A5 and TE-5C2D12 with a purity of more than 95% (stored at -20°C).
[0108] 2. Ascites Preparation
[0109] Balb / c mice were intraperitoneally injected with sterile paraffin oil (0.5 mL / mouse). Fifteen days later, hybridoma cell lines TE-1E10A5 and TE-5C2D12 (1×106 After 7-10 days, ascites was collected and purified by Protein A affinity chromatography. The ascites was then transferred to a dialysis bag and dialyzed in 0.01 M PBS buffer (pH 7.4). The liquid in the dialysis bag was then collected to obtain monoclonal antibodies TE-1E10A5 and TE-5C2D12 with a purity of over 95%, respectively. The antibodies were filtered through a 22 μm sterile filter membrane and stored at -20°C.
[0110] The monoclonal antibodies TE-1E10A5 and TE-5C2D12 used in subsequent steps and examples were all prepared from ascites.
[0111] 2. Potency detection (indirect ELISA method)
[0112] 1. Prepare an ELISA plate and add coating solution (100 μL / well). Coat overnight at 4°C. Coating solution: Dilute recombinant trypsin (RPT) with 0.05 M carbonate buffer (pH 9.6) to a protein concentration of 5 μg / mL.
[0113] 2. After completing step 1, take the ELISA plate and wash it three times with PBST solution. Then add blocking solution (200 μL / well) and incubate at 37°C for 2 hours. Blocking solution: PBST solution containing 0.5g / 100mL BSA.
[0114] 3. After completing step 2, remove the ELISA plate and wash it three times with PBST. Dilute the TE-1E10A5 and TE-5C2D12 monoclonal antibodies to a base concentration of 1 mg / ml using PBS buffer (pH 7.4, 0.01 M). Antibody dilution solution: Take the monoclonal antibodies TE-1E10A5 and TE-5C2D12 and, based on the antibody concentration of 1 mg / ml (considered as 1-fold or original multiple), perform serial dilutions using PBS buffer (pH 7.4, 0.01 M) to obtain antibody dilution solutions of varying concentrations. Then, add the antibody dilution solution (100 μL / well) and incubate at 37°C for 1 hour.
[0115] 4. After completing step 3, remove the ELISA plate and wash three times with PBST. Then, add goat anti-mouse HRP-labeled secondary antibody working solution and incubate at 37°C for 0.5 h. HRP-labeled secondary antibody working solution: 1:5000 dilution of HRP-labeled secondary antibody. HRP-labeled secondary antibody: Kangwei Century brand, catalog number CW0102S.
[0116] 5. After completing step 4, take the ELISA plate, wash it with PBST solution three times, then add TMB substrate reaction solution to develop color for 10 minutes, then add 2M sulfuric acid solution to stop the color development, and then measure the absorbance at 450nm with an ELISA reader (see Table 2).
[0117] Table 2. Results of titer determination of monoclonal antibodies at different concentrations
[0118]
[0119] As shown in the results in Table 2 , the titers of monoclonal antibodies TE-1E10A5 and TE-5C2D12 were both ≥1.28 million.
[0120] 3. Antibody Specificity Test
[0121] The test method is the same as step 2 above, but the coating solution and antibody diluent are replaced.
[0122] Other enzyme protein preparations with the same protein expression system as recombinant trypsin protein (RPT): recombinant carboxypeptidase B protein (RCPB), recombinant enterokinase protein (REK), sperm-specific protein (SP10) expressed in other Escherichia coli systems, bovine serum albumin (BSA), negative serum, and recombinant RPT protein (prepared in Example 1) were selected for coating plates, and purified RPT antibodies TE-1E10A5 and TE-5C2D12 were added at a concentration of 0.1 μg / mL, respectively, to test the reaction of the antibodies with these proteins.
[0123] The results are shown in Figure 1, indicating that monoclonal antibodies TE-1E10A5 and TE-5C2D12 only interact (bind) with RPT and do not cross-react with other proteins, indicating high specificity.
[0124] IV. Antibody subtype identification
[0125] Antibody subtypes were identified using a commercially available Ig class / subclass / subtype identification kit (Luoyang Bio-Tong Laboratory Materials Center, Cat. No. C060101-L). The results are shown in Table 3.
[0126] Table 3. Identification results of TE-1E10A5 and TE-5C2D12 antibody subtypes*
[0127] Subtype TE-1E10A5 TE-5C2D12 Positive control Negative control IgG1 2.086 1.962 2.702 0.054 IgG2a 0.066 0.07 2.747 0.066 IgG2b 0.098 0.082 2.725 0.061 IgG3 0.069 0.051 2.708 0.068 IgM 0.061 0.055 2.660 0.063 IgA 0.058 0.062 2.680 0.059 Kappa 1.701 1.399 2.647 0.07 Lambda 0.073 0.056 2.639 0.069
[0128] *Note: The values in the table represent the absorbance values at OD450nm.
[0129] The results showed that the antibody TE-1E10A5 was of IgG1 subtype, the antibody TE-5C2D12 was of IgG1 subtype, and the light chains of both antibodies were Kappa chains.
[0130] Example 3. Preparation of ELISA detection kit
[0131] 1. Preparation of HRP-labeled antibodies
[0132] Weigh 1 mg of HRP and dissolve it in deionized water at a concentration of 10 mg / ml in a volume of 0.1 ml. Add 0.1 ml of freshly prepared 0.1 mol / L NaIO4 solution to the prepared HRP solution, equal to the volume of the enzyme solution, dropwise, and react in the dark at 4°C for 30 minutes until the reaction solution turns dark green. Add 0.1 ml of 0.5% ethylene glycol dropwise, mix well, and react in the dark at 4°C for 30 minutes until the reaction solution turns brown. Add 1 mg of monoclonal antibody TE-1E10A5, mix well, place the antibody and activated enzyme in a dialysis bag, and dialyze in 50 mM CBS buffer at pH 9.6 at 4°C overnight. Remove the dialyzed fraction and add 20 μL of freshly prepared 5 mg / ml NaBH4 solution, keep in the dark for 1 hour; then add an equal volume of saturated (NH4)2SO4 solution to precipitate the protein, centrifuge at 5000rpm for 30min; remove the supernatant, resuspend the precipitate with 50% (NH4)2SO4 solution, and centrifuge at 5000rpm for 30min; dissolve the precipitate with PBS, then desalt using a desalting column, add an equal volume of glycerol as a protective agent to obtain the enzyme-labeled antibody TE-1E10A5, and store it at -20℃ after aliquoting.
[0133] 2. Preparation of Coated Plates
[0134] Dilute the monoclonal antibody TE-5C2D12 in carbonate buffer to a final concentration of 4 μg / mL. Pipette 100 μL / well of the diluted antibody into a PVC microtiter plate. Cover the plate with sealing film and incubate at 4°C overnight. Discard the coating solution, wash the plate three times with PBST, and block the plate with PBST buffer containing 0.5% BSA, adding 200 μL per well. Cover the plate with sealing film and incubate in a 37°C incubator for 2 hours. Wash the plate three times with PBST. After drying, seal the coated plate in an aluminum foil bag and store at 4°C.
[0135] 3. How to use the ELISA test kit (double antibody sandwich method)
[0136] Remove the coated plate (coated with TE-5C2D12), return to room temperature, use a pipette to draw 100 μL of positive standard control (10 ng / mL recombinant RPT, dilute the positive standard with phosphate buffer as needed to obtain different series of positive control solutions), blank control (0.01M PH7.4 phosphate buffer) and the sample to be tested, and add them to the corresponding reaction wells; then add 100 μL of enzyme-labeled antibody TE-1E10A5 (250 ng / mL) to each reaction well, shake gently for 10-15 seconds, cover the ELISA plate with a plate cover or cover with a sealing film, and incubate at 37°C for 0.5 hours; after the incubation is complete, remove the plate cover or sealing film, quickly flip the ELISA plate, discard the liquid in the plate well into the waste tank, and pat dry on absorbent paper. After washing the plate 3-5 times with PBST, add 100 μL Allow the TMB substrate solution to develop color for 10 minutes, then add 50 μL of stop solution (2 M sulfuric acid). Measure the optical density of each well at 450 nm on a microplate reader. Draw a standard curve with the standard concentration as the horizontal axis (X) and the OD value as the vertical axis (Y). Substitute the OD value of the sample well into the standard curve equation to obtain the protein quantification value for the corresponding sample.
[0137] Example 4: Sensitivity and specificity determination of the kit
[0138] 1. Sensitivity test of ELISA test kit
[0139] The kit of Example 3 was analyzed to test its sensitivity. 0.01 M PBS diluent was used as the test sample (the number of samples selected was ≥30 at 0 ng / ml), as shown in Table 4.
[0140] Table 4. Kit sensitivity test results
[0141] Serial number OD value Serial number OD value Serial number OD value 1 0.060 11 0.055 21 0.055 2 0.059 12 0.055 22 0.059 3 0.055 13 0.057 23 0.058 4 0.055 14 0.057 24 0.057 5 0.059 15 0.055 25 0.054 6 0.057 16 0.055 26 0.055 7 0.056 17 0.056 27 0.052 8 0.059 18 0.059 28 0.056 9 0.058 19 0.057 29 0.056 10 0.057 20 0.058 30 0.057
[0142] Calculate the mean and variance of the 30 samples and substitute them into the equation Y = OD mean + 2 × OD variance. Substitute the Y value into the equation of the standard curve to obtain the X concentration value, which is the sensitivity.
[0143] It was determined that the detection sensitivity of the kit of Example 3 was 0.049 ng / mL.
[0144] 2. Kit-Specific Detection
[0145] The kit of Example 3 was analyzed to test its specificity.
[0146] Other enzyme protein preparations expressed in the same protein expression system as recombinant trypsin (RPT) were selected: 1. Recombinant carboxypeptidase (100 ng / ml), 2. Recombinant enterokinase (100 ng / ml), 3. Sperm-specific protein SP10 expressed in other Escherichia coli systems (100 ng / ml), 4. 1% BSA, 5. Blank culture medium for E. coli, 6. Blank culture medium for yeast, 7. DMEM blank culture medium, 8. Blank culture medium for MEM cells, 9. Blank culture medium for 1640 cells, 10. Mouse negative serum as a negative control, 11. pH 7.4, 0.01 M PBS buffer as a blank control, and 12. Recombinant trypsin (RPT) (100 ng / ml) as a positive control. Absorbance at 450 nm was measured using a microplate reader (see Table 5). Specificity detection methods were the same as described above. The results are shown in Table 5.
[0147] Table 5. Kit specificity determination results
[0148]
[0149]
[0150] The results showed that the monoclonal antibody in the kit only reacted with RPT and did not cross-react with other proteins, with ideal specificity.
[0151] 3. Determination of the detection limit of the kit
[0152] The kit of Example 3 was analyzed to test its detection limit.
[0153] Using 0.01M pH 7.4 phosphate buffer as diluent, recombinant trypsin protein (RPT) was diluted in a gradient manner and used as the test sample. 0.01M pH 7.4 phosphate buffer was used as the blank sample. The upper and lower limits of the test kit were determined. Figure 2 and Figure 3 shown.
[0154] The results are as follows Figure 2 and Figure 3 As shown in the figure, the upper limit of detection of the recombinant trypsin detection kit is 40 ng / ml, and the lower limit of detection is as low as 0.02 ng / ml.
[0155] Biomaterial Deposit
[0156] The hybridoma cell line TE-1E10A5 isolated and obtained in the present invention has been deposited with the China Center for Type Culture Collection (CCTCC; Wuhan University, Wuhan, China) on January 31, 2023, with the accession number CCTCC NO: C202320. Testing by the CCTCC confirmed that the cell line is viable.
[0157] The hybridoma cell line TE-5C2D12 isolated and obtained in the present invention has been deposited with the China Center for Type Culture Collection (CCTCC; Wuhan University, Wuhan, China) on January 31, 2023, with the accession number CCTCC NO: C202321. Testing by the CCTCC confirmed that the cell line is viable.
[0158] The above-described embodiments merely represent several implementation methods of the present invention, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art may make several modifications and improvements without departing from the scope of the present invention, and these modifications and improvements fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be based on the appended claims. At the same time, all documents mentioned in this application are cited as references in this application, just as if each document was cited as a reference individually.
Claims
1. A kit for detecting trypsin protein, the kit comprising: (i) a monoclonal antibody secreted by a hybridoma cell line having a deposit number of CCTCC NO: C202321; and (ii) a monoclonal antibody secreted by a hybridoma cell line having a deposit number of CCTCC NO: C202320.
2. The kit according to claim 1, characterized in that These include: A solid phase carrier, wherein the solid phase carrier is coated with a first monoclonal antibody, wherein the first monoclonal antibody is selected from the monoclonal antibody of (i) or (ii); and A container or package a, wherein the container or package a contains a second monoclonal antibody, wherein the second monoclonal antibody is selected from the monoclonal antibody of (ii) or (i); Wherein, the second monoclonal antibody carries a detectable marker; or, the kit comprises a detectable marker for connecting to the second monoclonal antibody; The first monoclonal antibody and the second monoclonal antibody are different and can bind to the trypsin protein at the same time.
3. The kit according to claim 1 or 2, characterized in that The kit further comprises one or more components selected from the following: (a) a container or package b, wherein the container or package b contains a trypsin protein standard (positive standard); and / or (b) a container or package c, wherein the container or package c contains a quality control product of trypsin protein; preferably, the quality control product includes a positive quality control product and a negative quality control product; (c) a container or package d, wherein the container or package d contains a substrate corresponding to a detectable marker; (d) a container or package e, wherein the container or package e contains a developer; (e) a container or package f, wherein the container or package f contains a coating liquid; (f) a container or package g, wherein the container or package g contains a washing liquid; (g) a container or package f, wherein the container or package f contains a stop solution.
4. The kit according to claim 2, characterized in that The detectable labels include (but are not limited to): horseradish peroxidase, alkaline phosphatase, glucose oxidase, β-D-galactosidase, urease, catalase, or glucoamylase.
5. The kit according to claim 2, characterized in that The solid phase carrier includes: well plate, magnetic beads, microspheres, chips, glass slides, and test papers.
6. The kit according to claim 1 or 2, characterized in that The linear range of the kit is 0.02-40 ng / ml; and or The detection sensitivity of the kit is 0.049 ng / mL.
7. A monoclonal antibody that specifically binds to trypsin protein, selected from: (i) a monoclonal antibody secreted by a hybridoma cell line having a deposit number of CCTCC NO: C202321; (ii) a monoclonal antibody secreted by a hybridoma cell line having a deposit number of CCTCC NO: C202320.
8. Use of the monoclonal antibody according to claim 7 for preparing a kit for detecting trypsin protein; preferably, the detection includes quantitative detection, semi-quantitative detection or qualitative detection.
9. A hybridoma cell line that produces a monoclonal antibody that specifically binds to trypsin protein, selected from: A hybridoma cell line with a deposit number of CCTCC NO: C202321; The hybridoma cell line with the accession number of CCTCC NO:C202320.
10. A method for detecting trypsin protein, the method comprising the following steps: (a) adding a sample to be tested to a solid phase carrier coated with a first monoclonal antibody, so that the trypsin protein in the sample to be tested binds to the first monoclonal antibody on the solid phase carrier to form a solid phase carrier with a "trypsin protein-first monoclonal antibody" binary complex; (b) adding a second monoclonal antibody to the solid phase carrier obtained in (a), thereby forming a solid phase carrier with a "second monoclonal antibody-trypsin protein-first monoclonal antibody" ternary complex; and the second monoclonal antibody carries a marker; (c) detecting the marker in the ternary complex, thereby determining the presence and amount of trypsin protein in the sample to be tested; The additional condition is that step (a) and step (b) may be performed sequentially or simultaneously; Wherein, the first monoclonal antibody and the second monoclonal antibody are selected from: a monoclonal antibody secreted by a hybridoma cell line with a preservation number of CCTCC NO: C202321, and a monoclonal antibody secreted by a hybridoma cell line with a preservation number of CCTCC NO: C202320; preferably, the first monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell line with a preservation number of CCTCC NO: C202321, and the second monoclonal antibody is a monoclonal antibody secreted by a hybridoma cell line with a preservation number of CCTCC NO: C202320.
